Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica - PubMed

Affiliations

• PMID: 10691865
• DOI: 10.1046/j.1365-2141.2000.01868.x

Free article

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica

F Solé et al. Br J Haematol. 2000 Feb.

Free article

Abstract

Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.

Similar articles

• Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.

  Solé F, Luño E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Millà F, Ribera JM, Bureo E, Marquez ML, Arranz E, Florensa L. Solé F, et al. Haematologica. 2005 Sep;90(9):1168-78. Haematologica. 2005. PMID: 16154839

• [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].

  Qu SQ, Liu XP, Xu ZF, Zhang Y, Qin TJ, Zhang TJ, Cui R, Hao YS, Xiao ZJ. Qu SQ, et al. Zhonghua Xue Ye Xue Za Zhi. 2011 Dec;32(12):819-24. Zhonghua Xue Ye Xue Za Zhi. 2011. PMID: 22339954 Chinese.

• Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.

  Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y, Tanaka Y, Sakura T, Tsukamoto N, Karasawa M, Itoh K, Hirabayashi H, Sawamura M, Shinonome S, Shimano S, Miyawaki S, Nojima Y, Murakami H. Matsushima T, et al. Blood. 2003 May 1;101(9):3386-90. doi: 10.1182/blood-2002-03-0947. Epub 2002 Dec 27. Blood. 2003. PMID: 12506028 Review.

• Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes.

  Jotterand M, Parlier V. Jotterand M, et al. Leuk Lymphoma. 1996 Oct;23(3-4):253-66. doi: 10.3109/10428199609054828. Leuk Lymphoma. 1996. PMID: 9031106 Review.

Cited by

• Cytogenetic risk stratification in chronic myelomonocytic leukemia.

  Such E, Cervera J, Costa D, Solé F, Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, del Cañizo C, Gómez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF. Such E, et al. Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957. Epub 2010 Nov 25. Haematologica. 2011. PMID: 21109693 Free PMC article.

• Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

  Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP. Hosono N, et al. Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130. Oncotarget. 2017. PMID: 28031539 Free PMC article.

• [Analysis of the karyotype abnormalities and its prognostic in 298 patients with myelodysplastic syndrome].

  Yan X, Wei J, Wang J, Ren Y, Zhou X, Mei C, Ye L, Xie L, Hu C, Jin J, Tong H. Yan X, et al. Zhonghua Xue Ye Xue Za Zhi. 2015 Apr;36(4):297-301. doi: 10.3760/cma.j.issn.0253-2727.2015.04.008. Zhonghua Xue Ye Xue Za Zhi. 2015. PMID: 25916290 Free PMC article. Chinese.

• Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.

  Hunter A, Padron E. Hunter A, et al. Curr Hematol Malig Rep. 2021 Jun;16(3):247-255. doi: 10.1007/s11899-021-00613-9. Epub 2021 Mar 3. Curr Hematol Malig Rep. 2021. PMID: 33660195 Review.

• Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

  Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L. Itzykson R, et al. Hemasphere. 2018 Nov 29;2(6):e150. doi: 10.1097/HS9.0000000000000150. eCollection 2018 Dec. Hemasphere. 2018. PMID: 31723789 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal